Why the study?
Randomized trials of IABP in cardiogenic shock have included only ACS patients without stratifying by shock severity.
Does intra-aortic balloon pump reduce in-hospital mortality in patients with cardiogenic shock across different SCAI shock stages?
Population
934 cardiac intensive care unit patients with cardiogenic shock from any etiology
Comparison
IABP vs no IABP across SCAI shock stages
Design
Observational cohort study using inverse probability of treatment weighting
Follow-up
In-hospital
Key result
Intra-aortic balloon pump use in cardiogenic shock was associated with lower in-hospital mortality (27% vs. 43%; adjusted OR 0.53; 95% CI 0.40-0.72; p<0.0001) across all SCAI shock stages.
Authors
Loading...
IABP should not yet change practice in cardiogenic shock; leaves open mortality benefit across SCAI stages pending randomized confirmation.
Observational (n=934)
Does intra-aortic balloon pump reduce in-hospital mortality in patients with cardiogenic shock across different SCAI shock stages?
Effect estimate: OR 0.53 (95% CI 0.40-0.72)
Absolute Event Rate: 27% vs 43%
p-value: p=<0.0001
In a retrospective cohort of cardiogenic shock patients, IABP use was associated with significantly lower in-hospital mortality across all SCAI shock stages.
Jentzer et al. (2021) conducted an observational in Cardiogenic shock (n=934). Intra-aortic balloon pump (IABP) vs. No IABP was evaluated on In-hospital mortality (OR 0.53, 95% CI 0.40-0.72, p=<0.0001). Intra-aortic balloon pump use in cardiogenic shock was associated with lower in-hospital mortality (27% vs. 43%; adjusted OR 0.53; 95% CI 0.40-0.72; p<0.0001) across all SCAI shock stages.